Health Care • Biotechnology: Pharmaceutical Preparations
$15.90 ▼ -0.02
(-0.13%)
MKT CAP: $2.21B • VOL: 2.29M
52W L $9 52W H $21
PRGO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.25B | $4.37B | $4.66B |
| YoY Revenue Growth % | -2.8% | -6.1% | — |
| Gross Profit | $1.49B | $1.54B | — |
| Gross Margin % | 35.1% | 35.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.12B | $112.9M | $151.9M |
| Operating Margin % | -26.4% | 2.6% | 3.3% |
| Net Income (GAAP) | -$1.43B | -$171.8M | -$12.7M |
| EBITDA (Normalized) | -$1.05B | $207.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $238.5M | $362.9M | $405.5M |
| Capital Expenditures (CapEx) | $93.4M | $118.3M | — |
| Free Cash Flow (FCF) | $145.1M | $244.6M | $405.5M |
| FCF Margin % | 3.4% | 5.6% | 8.7% |
| Return on Invested Capital (ROIC %) | -13.6% | 1.2% | — |
| Cash & Short-Term Equivalents | — | $558.8M | — |
| Total Debt (Short + Long Term) | $3.60B | $3.58B | — |
| Total Stockholders' Equity | $2.94B | $4.32B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRGO.